For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
ALC.10 (MM1OA-EA02), another myeloMATCH study, has opened in Canada comparing the usual treatment for FLT3 mutated acute myeloid leukemia (AML) with a new drug using two different treatment schedules to see if it improves outcomes for older patients.
The interim results of the GCC.1 / S1823 study were presented at ASCO 2026 during the Genitourinary Cancer Session. The study focuses on patients with early-stage germ cell tumors and the blood biomarker microribonucleic acid (miRNA) 371a-3p (called miR371). The presence of miR371 may allow clinicians to identify patients at higher risk of relapse earlier and more accurately than current monitoring approaches.
Final results from the CCTG HN.9 (EORTC 1740-HNCG) were presented at ASCO 2026, highlighting the challenges of reducing treatment intensity while maintaining outcomes for patients with human papillomavirus (HPV)-positive oropharyngeal cancer. The study evaluated a cisplatin-free treatment approach combining immunotherapy (durvalumab) with radiation therapy in patients with intermediate-risk, HPV-positive, locally advanced oropharyngeal squamous cell carcinoma.
New findings presented at ASCO 2026 demonstrate that a structured exercise program for colon cancer survivors improves survival outcomes and reduces healthcare system costs.
